All In Biotech

Drug Trial Radar · NCT05104125

Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris

A Phase II Randomized, Double-blind, Placebo-controlled, Multi-center, Multi-dose Study to Evaluate Safety and Efficacy of ASC40 Tablets in Subjects With Moderate to Severe Acne Vulgaris.

Last checked: Nov 19, 2026Latest source record: May 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

180

Actual

Start

Jan 12, 2022

Primary completion

Apr 10, 2023

Study completion Apr 10, 2023

Sponsor

Sponsor type
Industry
First posted
Nov 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase2, randomized, double-blind, multi-center, multi-dose and placebo parallel controlled design. The subjects in the study group were given double-blind drugs, and they were taken (orally) after dinner every day according to the requirements of clinical trial scheme.

Conditions

  • Acne Vulgaris

Interventions

  • ASC40 25mgDrug

    25mg of ASC40 orally once daily for 12 weeks.

  • ASC40 50mgDrug

    50mg of ASC40 orally once daily for 12 weeks.

  • ASC40 75mgDrug

    75mg of ASC40 orally once daily for 12 weeks.

  • PlaceboDrug

    Placebo orally once daily for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change of total lesion count compared with baseline and week 12.Time frame: Baseline to week 12
  2. Ratio of subjects, whose IGA grades was decreased by ≥2 grades compared with baseline at week 12.Time frame: Baseline to week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huashan Hospital Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.